Accelerating the development of new drugs for neurological conditions
Official title: BPN PROJECT BPN-36938
Funded at Albany Molecular Research, INC. · NIH-11201259 · Data updated 2026-11-12
This study is all about finding and creating new medicines for brain-related conditions faster, so that patients can have more treatment options that are safe and effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albany Molecular Research, INC. NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | September 17, 2024 |
| Project end | September 16, 2030 |
| Funding year | 2024 |
| Award (this year) | $1,089,593 |
| NIH project number | 271201500005I-0-759502400001-1 |
| Project ID | NIH-11201259 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are individuals with neurological conditions who may be eligible for new drug trials.
✕Less likely to help
Patients with conditions unrelated to neurological disorders may not receive any benefit from this research.
What this research studies
This research focuses on speeding up the discovery and development of new drugs specifically for neurological conditions. It involves a comprehensive approach that includes the development and manufacturing of drug formulations suitable for clinical trials. The program ensures that all processes adhere to strict regulatory standards, including Good Manufacturing Practices, to guarantee the safety and efficacy of the drugs being developed. Patients may benefit from new treatment options that emerge from this initiative.
Why it matters
Potential benefit: If successful, this research could lead to the development of innovative drugs that improve treatment options for patients with neurological disorders.
How similar studies have gone: Previous initiatives in drug development for neurological conditions have shown promise, indicating that this approach has the potential for success.
Where this research is happening
-
Albany Molecular Research, INC.
Albany, United States Active
Researchers
- Principal investigator: Meitz, Susan — Albany Molecular Research, INC.
- Study coordinator: Meitz, Susan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.